Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis

Odelia Amit, Gil Fridberg, Yakir Moshe, Inna Ospovat, Yehonatan Sherf, Dina Tshernichovsy, Chen Karni, Irit Avivi, Ron Ram

Blood (2025) 146 (Supplement 1): 5973.

https://doi.org/10.1182/blood-2025-5973

Published: 2025

Journal Articles

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Blood (2025) 146 (Supplement 1): 1937.

https://doi.org/10.1182/blood-2025-1937

Published: 2025

Journal Articles

Predictive model based on post CAR-T cell therapy cytokine signature can help predict cytopenia

Noam Benyamini, danielle sapir, keren Silberpfennig, Onit Alalouf, Tsofia Levi, Shimrit Harlev, Ron Ram, Yoav Shechtman, Ofrat Beyar-Katz, Keren Asayag

Blood (2025) 146 (Supplement 1): 2383.

https://doi.org/10.1182/blood-2025-2383

Published: 2025

Journal Articles

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Blood (2025) 146 (Supplement 1): 130.

https://doi.org/10.1182/blood-2025-130

Published: 2025

Journal Articles

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Blood (2025) 146 (Supplement 1): 5494.

https://doi.org/10.1182/blood-2025-5494

Published: 2025

Journal Articles

Cladribine-based regimens for Relapsed/Refractory Acute Myeloid Leukemia – a real-world multicenter retrospective study

Liat Shargian, Maya Zlotnick, Ron Ram, Odelia Amit, Adi Sherban, Ofir Wolach, Adi Schacham Abulafia, Boaz Nachmias, Chezi Ganzel, Drorit Merkel, Meirav Kedmi, Abraham Avigdor, Irina Amitai

Blood (2025) 146 (Supplement 1): 6969.

https://doi.org/10.1182/blood-2025-6969

Published: 2025

Journal Articles

Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study

Gil Fridberg, Odelia Amit, Mohamad Ganayem, Felix Bukstein, Chava Perry, Irit Avivi Mazza, Ronit Gold, Ron Ram

Blood (2024) 144 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2024-204837

Published: 2024

Journal Articles

Single Cell Analysis of Pre-Treatment Peripheral Immune Composition Can Predict CAR-T Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Anna Gurevich Shapiro, Eitan Winter, Pascale Zwicky, Mor Zada, Noam Shapira, Oren Barboy, Paulina Chalan, Reut Sharet-Eshed, Merav Kedmi, Eyal David, Irit Mazza Avivi, Assaf Weiner, Ron Ram, Ido Amit

Blood (2024) 144 (Supplement 1): 4788.

https://doi.org/10.1182/blood-2024-203893

Published: 2024

Journal Articles

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

Ben Varon, Ron Ram, Avichai Shimoni, Batia Avni, Sigal Grisariu, Vered Stavi, Yael Bar-On, Moshe Yeshurun, Ronit Elhasid, Aharon Gefen, Asaf Yanir, Odelia Amit, Dana Yehudai-Ofir, Israel Henig, Tsila Zuckerman

Blood (2024) 144 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2024-206874

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Eitan Kugler, Inbar Cohen, Ron Ram, Jonathan Canaani, Irina Amitai, Liat Shargian, Boaz Nachmias, Baher Krayem, Avraham Frisch, Itay Levi, Luiza Akria, Pia Raanani, Ofir Wolach, Eitan Kugler

Blood (2023) 142 (Supplement 1): 5911.

https://doi.org/10.1182/blood-2023-185488

Published: 2023

Journal Articles

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Blood (2023) 142 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2023-174883

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Ido Wolf, Odelia Amit, Ronit Yerushalmi, Yakir Moshe, Noga Shem-Tov, Gil Fridberg, Ivetta Danylesko, Irit Avivi Mazza, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2023-182826

Published: 2023

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq

Ron Ram, Yonatan Katzenelenbogen, Anna Gurevich Shapiro, Eitan Winter, Oren Barboy, Mor Zada, Shahar Halevi, Eyal David, Irit Avivi Mazza, Ido Amit

Blood (2023) 142 (Supplement 1): 4829.

https://doi.org/10.1182/blood-2023-190639

Published: 2023

Journal Articles

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Gil Fridberg, Odelia Amit, Liat Shargian, Ofrat Beyar Katz, Sigal Grisariu, Chava Perry, Ronit Gurion, Batia Avni, Tsila Zuckerman, Irit Avivi Mazza, Ron Ram

Blood (2023) 142 (Supplement 1): 4886.

https://doi.org/10.1182/blood-2023-188473

Published: 2023

Journal Articles

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Mazyar Shadman, Matthew J Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini

Blood (2023) 142 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2023-180233

Published: 2023

Journal Articles

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 7509–7511.

https://doi.org/10.1182/blood-2022-169459

Published: 2022

Journal Articles

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Odelia Amit, Shai Winer, Yakir Moshe, Pia Raanani, Eitan Kugler, Moshe Yeshurun, Irit Avivi, Ofir Wolach

Blood (2022) 140 (Supplement 1): 10637–10638.

https://doi.org/10.1182/blood-2022-164543

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis

Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition

Predictive model based on post CAR-T cell therapy cytokine signature can help predict cytopenia

Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party

Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition

Cladribine-based regimens for Relapsed/Refractory Acute Myeloid Leukemia – a real-world multicenter retrospective study

Standardization Protocol to Mitigate Progression of Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) in Elderly Patients Treated with CD28 Co-Stimulatory Anti-CD19 CAR-T Cells - a Pilot Study

Single Cell Analysis of Pre-Treatment Peripheral Immune Composition Can Predict CAR-T Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study

Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq

Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)

Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only